Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Long-Term Investments (2018 - 2023)

Historic Long-Term Investments for Arrowhead Pharmaceuticals (ARWR) over the last 12 years, with Q2 2023 value amounting to $42.8 million.

  • Arrowhead Pharmaceuticals' Long-Term Investments fell 7420.44% to $42.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $42.8 million, marking a year-over-year decrease of 7420.44%. This contributed to the annual value of $105.9 million for FY2022, which is 5689.16% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Long-Term Investments of $42.8 million as of Q2 2023, which was down 7420.44% from $78.8 million recorded in Q1 2023.
  • Arrowhead Pharmaceuticals' 5-year Long-Term Investments high stood at $245.6 million for Q3 2021, and its period low was $26.3 million during Q4 2019.
  • Its 5-year average for Long-Term Investments is $122.9 million, with a median of $113.4 million in 2020.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Long-Term Investments surged by 32120.7% in 2020 and then tumbled by 7420.44% in 2023.
  • Arrowhead Pharmaceuticals' Long-Term Investments (Quarter) stood at $26.3 million in 2019, then surged by 321.21% to $110.9 million in 2020, then surged by 96.21% to $217.6 million in 2021, then plummeted by 46.78% to $115.8 million in 2022, then plummeted by 63.04% to $42.8 million in 2023.
  • Its last three reported values are $42.8 million in Q2 2023, $78.8 million for Q1 2023, and $115.8 million during Q4 2022.